Objective: To evaluate the effectiveness of two kinds of Arg-Gly-Asp (RGD)-targeted 131 I-containing nanoliposomes for the treatment of cervical cancer in vitro and in vivo. Methods: The nanoparticle liposomes designated RGD-131 I-tyrosine peptide chain (TPC)-L and 131 I-RGD-L were prepared. The emulsion solvent evaporation method was used to encapsulate the polypeptide into liposomes. The quantity of entrapped polypeptide was measured using UV spectrophotometry. The labeling rates, radiochemical purities, and total radioactivities were measured using paper chromatography. Cytotoxicity was assessed using the MTS assay and flow cytometry. Therapeutic efficacy was monitored using a mouse xenograft model of cervical cancer. Results: The labeling efficiency, radiochemical purity, and specific radioactivity of RGD- 
Introduction
Cervical cancer is one of the most common cancers, 1 with a global incidence of 11.7% and an incidence of 13.4% in Chinese women. 2 The frequencies of cervical cancer are increasing, particularly for younger women. 3, 4 The 5-year survival rates of patients with stage IV cervical cancer range from 20% to 30%, and the long-term rate of tumor recurrence is less than 30%. 5, 6 There is special emphasis on how to select a treatment strategy to improve the quality of life of cancer survivors. 131 I emits highenergy X-rays and serves as an internal radiotherapeutic agent that can induce the killing of thyroid cancer cells by damaging their DNA through the effects of ionizing radiation. 7 131 I inhibits the growth of cervical cancer-derived HeLa cells, and although 131 I only binds to the surface of thyroid cells, it cannot be internalized into other cancer cells that do not express sodium/ iodide symporters. 8 The development of nanomedicine provides a promising approach for enhancing drug delivery. The targeting of radionuclide-containing liposomes through internal radiotherapy is employed for imaging and treatment of tumor models using passive and active nanoparticle targeting to improve the biodistribution of pharmacological therapeutics. 9 The purpose of the present study was to analyze the differences in the therapeutic effects of 131 I incorporated into a tyrosine polypeptide chain (TPC) labeled with 131 I on tyrosine residues that was encapsulated into liposomes as well as the effects of liposomes directly labeled with 131 I.
Materials and methods

Materials
Liposome RGD-bovine serum albumin (BSA)-polycaprolactone (PCL) was synthesized and provided by Professor Chang Jin, Tianjin University. 10 Tyrosine peptide chain (TPC) and a peptide with a random sequence (random peptide chain [RPC]) were purchased from the Chinese Peptide Company (Hangzhou, China). The TPC and RPC sequences were YYYHYYK YYRYHYYYRYYHYYKY and HPLG SPGSASDLETSGLEEQR, respectively.
131
I-Na was purchased from the China Institute of Atomic Energy, Beijing, China.
Cell lines
The HeLa cervical cancer cell line was cultured in Dulbecco's Modified Eagle's medium supplemented with 10% fetal bovine serum (GIBCO Cell Culture [subsidiary of Invitrogen Corp.], Carlsbad, CA, USA), and 1% penicillin/streptomycin (Beijing Dongsheng Tebo Technology Company, Beijing, China). Cells were stored in a humidified atmosphere containing 5% CO 2 buffered with ambient air at 37 C. The RGD peptide was overexpressed in HeLa cells.
11,12
I labeling
The liposomes and TPC were labeled with 131 I using the chloramine-T method. 13 The 131 I-liposomes and 131 I-TPC were purified using centrifugal filtration (Amicon Pro Purification System, Merck Millipore, Billerica, MA, USA) to remove the remaining 131 I-Na. The dose of radioactivity, radiochemical purity, and the rates of incorporation of radioactivity into the products were determined using paper chromatography. 14 The developer was prepared using a 3:2:5 ratio of butyl alcohol:2 ethyl alcohol:5 ammonium hydroxide.
Preparation of 131 I-labeled liposomes
131
I-labeled liposomes were prepared as follows: 15 The RGD-targeting liposome encapsulating an RPC was directly labelled Figure 1a -1b. The emulsion solvent evaporation method was performed to encapsulate TPC or RPC into liposomes. The procedure was as follows: 2 mg of liposomes were dissolved in 2 mL of deionized water and then 300 mL of trioxymethylene solution was added. Immediately after the trioxymethylene and liposomes were sonicated (SCIENTZ-IID; Xin Zhi Biotechnology Co., Ltd., Zhejiang, China), the mixture was vibrated and centrifuged. The quantity of bound polypeptide was measured using a UV-visible spectrometer (UV-2450; Shimadzu Corporation, Beijing, China) at 220 nm.
Cellular uptake of 131 I
The RGD-BSA-PCL liposome was labeled with fluorescein isothiocyanate (FITC), 10 which can be easily imaged using confocal laser scanning microscopy (CLSM). The cellular uptake, targeting, and therapeutic effects of RGD-BSA-PCL are published. 16 CLSM was used to evaluate the uptake by HeLa cells of FITC-labeled liposomes that encapsulated TPC or RPC.
Cellular uptake of 131 I-RGD-L and RGD-131 I-TPC-L Cervical cancer-derived HeLa cells were seeded in 6-well plates and cultured with 1.85 MBq/mL of radioactive nanoliposomes. 16 Cells were washed, lysed, centrifuged, and counted at different times. Radioactivity was measured using a c-counter (LKB Gamma Counter 1261; LKB Instruments, Mount Waverley, Australia). All of experiments were performed in triplicate.
Apoptosis assays
The MTS assay was conducted according to a published procedure 17 
Mouse model
BALB/c mice (female, aged 4-5 weeks, 15 to 20 g) were purchased from the Beijing Experimental Animal Center of Peking Union Medical, China. Mice were kept under specific pathogen-free conditions in the Laboratory Animal Center of Tianjin Medical University, China. All animal studies were conducted in accordance with a protocol approved by the Tianjin Medical University General Hospital Ethics Committee. The animal experiment guidelines were followed according to the regulations of Swiss veterinary law.
HeLa cells were subcutaneously injected into the right flank. When the tumor volume reached 0.7 cm in diameter, the mice were randomly divided into three groups of five mice each. According to the principles of the human thyroid perchlorate discharge test, 0.05 mg/mL sodium perchlorate was added to the drinking water of all mice 1 day before injection of the radionuclide. 19 The mice were killed when neurological symptoms appeared or a loss of 20% of original body weight. 
Distribution of 131 I in mice
Mice were sacrificed at 24, 48, and 72 hours postinjection. Heart, spleen, liver, kidney, and tumor samples were collected for weighing, and radioactivity was measured using a c-counter. The percentage injected dose (ID) per gram of tissue was calculated. 20 
Radioiodine therapy
When a tumor's diameter reached 0.7 cm, 74 MBq of 131 I-labeled liposomes, 131 I-Na, or an equivalent volume of normal saline was injected into the tumor. During treatment, the animal's body weight and in vivo tumor growth were measured. Body weights and tumor volumes (volume
were measured. Antitumor activity was evaluated by determining the relative tumor increase rate (T/C) as follows: T/C (%) ¼ TRTV/CRTV x 100. Therapeutic efficiency was evaluated as follows: T/C >40% indicated no therapeutic effect, whereas T/C 40% (P<0.05) indicated a positive therapeutic effect. The tumor inhibition rate (TIR) was calculated by comparing the weights of the transplanted tumors of the treatment group with those of the negative control group as follows: TIR (%) ¼ (1-mean weight of the transplanted tumor of the treatment group per mean weight of the transplanted tumor of the negative control group) Â 100. 21 The therapy groups were followed for 30 days after injection and then killed.
SPECT/CT whole-body imaging of mice
To assess the organ localization of 131 I, single-photon computed tomography/computed tomography (SPECT/CT) (Discovery VH 670; GE, Chicago, IL, USA) was performed. Mice from the three treatment groups, except for the normal saline group, received an intratumor injection of 74 MBq (740 MBq/mL) of radioliposomes and Na 131 I, respectively.
22
Histopathology studies
When the radioiodine therapy experiment concluded, normal tissues including the heart, liver, spleen, and kidney were isolated. Sections were stained with hematoxylin and eosin for histopathological analyses. The histopathological changes of the tissue were examined using light microscopy, Â40 magnification (Olympus Th4-200; Olympus Optical Company, Beijing, China ).
Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics, version 22.0 (IBM Corp., Armonk, NY, USA). Data were evaluated using the Student t test or oneway ANOVA. The difference between the two groups was considered significant when the P<0.05 indicated a significant difference between two groups. 
Results
Characteristics of nanoparticles
Dynamic light scattering measurements showed that the diameters of RGD-TPC-L and RGD-L were not significantly different (264.7 AE 17.6 nm and 275.4 AE 18.7 nm, respectively) (Figure 1c) . The polydispersity index was 0.17, and the zeta potential was À41.30 mV.
Encapsulation of TPC and RPC into liposomes
The amounts of TPC or RPC encapsulated into liposomes using 100 mg, 200 mg, 300 mg, 500 mg, and 1000 mg of starting material were not significantly different. 
Internalization of liposome-encapsulated polypeptides
Confocal microscopy was used to evaluate the internalization of liposomes in HeLa AE 4.66% ID/g, 9.9 AE 2.11% ID/g, and 3.6 AE 1.03% ID/g, respectively, and were significantly higher compared with those of the Na 131 I group (0.41 AE 0.12% ID/g, 0.31 AE 0.08% ID/g, 0.29 AE 0.10% ID/g (Figure  2g-2j) . However, the uptake of all radionuclides was low and differed slightly among organs such as the heart, liver, spleen, and kidneys at all times.
Radiotherapy
The differences between in vivo and in vitro experiments required further evaluation of radioactive iodine treatment of cervical cancer using two types of nuclear liposomes. Therefore, a mouse xenograft model of cervical cancer was established. The average tumor volumes of the RGD- The TIR values of the RGD-131 I-TPC-L group were higher compared with those of the other groups, and the differences among these groups were significant (P < 0.01) (Figure 2k ). These results show that RGD-131 I-TPC-L had the best therapeutic effects in our mouse model of cervical cancer.
Histopathological analysis
To test the potential toxicity of liposomes in experimental mice, hematoxylin and eosinstained sections of the heart, liver, spleen, and kidneys were examined after radiotherapy. The histopathological images of the major organs are shown in Figure 2g Strategies for labeling or encapsulating radiolabeled nanoparticles include labeling nanoparticles during their preparation, labeling the nanoparticle's surface after encapsulation, labeling bioconjugates bound to the nanoparticle's surface after encapsulation, incorporation into the lipid bilayer after encapsulation by liposomes, and after loading of the aqueous phase of the liposomes. 24 Here, we first explored the properties of 131 I-TPC encapsulated into liposomes via self-assembly using the emulsion solvent evaporation method. Previous in vivo biodistribution and pharmacokinetics studies 131 I used the standard chloramine-T oxidation method to conjugate 131 I to the surface of a nanoparticle. 25 Certain peptides can be encapsulated into nanoparticle liposomes, such as a peptide integrin antagonist, which are encapsulated in poly-lactic acid/oxidized plasma polylactic acid nanoparticles to increase the half-life of therapeutics. 26 Such studies indicate that the intracellular concentration of the peptide can be as high as its extracellular concentration without causing significant apoptosis. The peptide encapsulated into nanoparticles can significantly improve the specificity of delivery of a cancer chemotherapeutic drug and can mitigate
